Kairos Pharma (KAPA) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing therapeutics to overcome immune suppression and drug resistance in cancer, with a portfolio of seven drug candidates targeting prostate, lung, breast cancer, and glioblastoma.

• Pipeline includes five immunotherapeutics (KROS 101, 102, 201, 301, 401) and two antibodies (ENV 105, ENV 205) addressing drug resistance and immune checkpoints.

• Key patents are licensed from Cedars-Sinai Medical Center and Tracon Pharmaceuticals; all operations are conducted virtually to maximize capital efficiency.

• Lead product ENV 105 is in Phase 2 for prostate cancer and Phase 1 for lung cancer; KROS 201 is preparing for a Phase 1 trial in glioblastoma.

Financial performance and metrics

• No revenue generated to date; net losses of $1.8 million in 2023 and $0.3 million for the three months ended March 31, 2024.

• Cash on hand as of March 31, 2024 was $40,000; accumulated deficit of $6.5 million.

• Operating expenses for Q1 2024 were $287,000, with research and development expenses increasing due to clinical trial activity.

• Auditors issued a going concern opinion due to recurring losses and limited cash resources.

Use of proceeds and capital allocation

• Estimated net proceeds of $5.6 million from the IPO (assuming $4.00 per share), with $1.0 million allocated to ENV 105 clinical trials, $0.7 million to pay accounts payable, and the remainder for working capital and general corporate purposes.

• Additional funding will be required beyond 12 months to support ongoing development and operations.